CDXS (Codexis) Short-Term Debt: $7.06 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDXS Codexis Inc CDXS
57 GF Score
Price $1.60
GF Value $2.57
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Codexis Short-Term Debt?

Codexis CDXS +1.60% 57 Short-Term Debt is $7.06 Mil as of Jun. 2026. GuruFocus rates CDXS with a GF Score™ of 57/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 6 warning signs investors should review.

Codexis's Short-Term Debt for the quarter that ended in Jun. 2026 was $7.06 Mil.

Codexis's quarterly Short-Term Debt stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($7.06 Mil).

Codexis Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Codexis Short-Term Debt Related Terms

Codexis Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Codexis's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Codexis Short-Term Debt Chart

Codexis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Codexis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 7.06
CDXS
57GF Score
Codexis Inc CDXS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $7.06 Mil mean?
Codexis (CDXS) has a Short-Term Debt of $7.06 Mil as of Jun. 2026.
Is Codexis' Short-Term Debt too high?
Codexis' current Short-Term Debt is $7.06 Mil. Overall, Codexis has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Codexis' Short-Term Debt compare to CUE and CNTB?
Codexis' Short-Term Debt of $7.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Codexis's current Short-Term Debt is $7.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Codexis stock overvalued right now?
Based on GuruFocus' analysis, Codexis (CDXS) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.60 — trading 37.9% below its estimated fair value. The current Short-Term Debt is $7.06 Mil. Codexis' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Codexis (CDXS), the current Short-Term Debt is $7.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Codexis (CDXS) Overvalued in 2026?

Based on GuruFocus' analysis, Codexis stock appears to be undervalued. The current stock price of $1.60 is trading 37.9% below its estimated GF Value™ of $2.57. GuruFocus considers Codexis to be Possible Value Trap.

Key valuation signals for CDXS:

  • Short-Term Debt: $7.06 Mil
  • GF Value™: $2.57 vs. price of $1.60 (37.9% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the CDXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Codexis Business Description

Other Exchanges 0I0X:UK4QK:Germany
Address 200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
57GF Score

Get the complete analysis for CDXS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$2.57
GF Value